Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · page 16 of 56
The chart uses a dual-axis approach to imply a safety-efficacy trade-off, positioning vedolizumab as the 'safest' and highly effective.
Pitch deck · competitive_analysis · compare_peers · dense density
Slide locked Sign in to view
Slide schematic 5/5
chart 1/1 list 1/1 quote 1/1 source-note 1/1 title 1/1
Components 5
bar-horizontal bullet pull-quote source-note headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1